Deniz Isık

Kartal Dr. Lutfi Kirdar City Hospital
Kartal, 34865, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Prognostic Significance of Preoperative PET-CT SUVmax in Resected Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.

Prognostic Significance of Preoperative PET-CT SUVmax in Resected Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.

Journal: Medicina (Kaunas, Lithuania)

Published: March 27, 2026

Association Between Body Mass Index and Clinical Outcomes of CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer: A Real-World Cohort Study.

Association Between Body Mass Index and Clinical Outcomes of CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer: A Real-World Cohort Study.

Journal: Journal of clinical medicine

Published: January 06, 2026

The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study.

The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study.

Journal: Journal of chemotherapy (Florence, Italy)

Published: December 19, 2025

The Effect of the Clinical-Pathological CPS+EG Staging System on Survival Outcomes in Patients with HER2-Positive Breast Cancer Receiving Neoadjuvant Treatment: A Retrospective Study.

The Effect of the Clinical-Pathological CPS+EG Staging System on Survival Outcomes in Patients with HER2-Positive Breast Cancer Receiving Neoadjuvant Treatment: A Retrospective Study.

Journal: Medicina (Kaunas, Lithuania)

Published: August 31, 2025

Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2- Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy.

Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2- Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy.

Journal: Current oncology (Toronto, Ont.)

Published: July 20, 2025

The Association of Khorana Risk Score with Venous Thromboembolism and Overall Survival in Patients with Metastatic Gastric Cancer.

The Association of Khorana Risk Score with Venous Thromboembolism and Overall Survival in Patients with Metastatic Gastric Cancer.

Journal: Medicina (Kaunas, Lithuania)

Published: April 11, 2025

Nutritional Indexes and Their Variations as Predictors of Atezolizumab Plus Chemotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer: A Turkish Oncology Group Study.

Nutritional Indexes and Their Variations as Predictors of Atezolizumab Plus Chemotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer: A Turkish Oncology Group Study.

Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)

Published: March 22, 2025

Very Favorable vs. Favorable Risk Groups in Metastatic Renal Cell Carcinoma: A Step Toward Personalized Treatment.

Very Favorable vs. Favorable Risk Groups in Metastatic Renal Cell Carcinoma: A Step Toward Personalized Treatment.

Journal: Cancers

Published: February 16, 2025

The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis.

The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis.

Journal: BMC cancer

Published: December 04, 2024

Trastuzumab Rechallenge in HER2-Positive Metastatic Breast Cancer: A Promising Strategy for Enhanced Progression-Free Survival Post Ado-Trastuzumab Emtansine Progression.

Trastuzumab Rechallenge in HER2-Positive Metastatic Breast Cancer: A Promising Strategy for Enhanced Progression-Free Survival Post Ado-Trastuzumab Emtansine Progression.

Journal: Medicina (Kaunas, Lithuania)

Published: November 06, 2024

Tumor-infiltrating lymphocytes as predictive biomarkers in neoadjuvant treatment of HER2-positive breast cancer.

Tumor-infiltrating lymphocytes as predictive biomarkers in neoadjuvant treatment of HER2-positive breast cancer.

Journal: The oncologist

Published: August 07, 2024

Clinical Effectiveness of Targeted Therapies Following Nivolumab Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-World Study.

Clinical Effectiveness of Targeted Therapies Following Nivolumab Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-World Study.

Journal: Medicina (Kaunas, Lithuania)

Published: June 11, 2024

Showing 1-12 of 17

Last Updated: 09/26/2026